Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal
Sanofi has taken a chance on Sino Biopharmaceutical’s first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up …
Post
-
-
Aspire Biopharma and Microsize collaborate for alprazolam powder formulation
Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of …
-
Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of …
-
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?
Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a …
-
Navigating uncertainty and building resilient supply chains: The case for US-based CDMO partnerships
Choosing to onshore pharmaceutical manufacturing by partnering with a US-based contract development and manufacturing organization (CDMO) can offer advantages for …
-
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat
French biotech OSE Therapeutics has shifted focus to its later-stage clinical assets as it looks to prioritise near-term value creation. OSE’s …
-
Pharma rings the changes as CEO shake-up continues
Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical …
-
Europe’s pharma trade with the US remains critical despite tariff turmoil
US government policies of Most Favored Nation (MFN) and tariffs threaten to disrupt Europe’s pharmaceutical trade, but while European countries …
-
Rallybio to acquire Candid Therapeutics
US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. Following completion, the combined …
-
Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production
Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated …
-
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed …
-
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026
Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing …
-
Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take
The European Medicines Agency’s (EMA) drug review committee has taken a positive stance on granting marketing authorisation to Moderna’s combination …
-
FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism
The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for the treatment of …
-
Sanofi receives CHMP recommendation for Dupixent expansion in Europe
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
